BVDV vaccination in North America: risks versus benefits.

about

Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): bovine viral diarrhoea (BVD)

P2860

Q47160377-7DB00258-697E-4D61-9F41-3634B7440112

P2860

BVDV vaccination in North America: risks versus benefits.

Item

http://www.wikidata.org/entity/Q38518785

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

BVDV vaccination in North America: risks versus benefits.

@en

type

Item

label

BVDV vaccination in North America: risks versus benefits.

@en

prefLabel

BVDV vaccination in North America: risks versus benefits.

@en

P1476

BVDV vaccination in North America: risks versus benefits.

@en

P2093

Philip J Griebel

http://www.w3.org/2001/XMLSchema#string

P2860

Generation and characterization of a hepatitis C virus NS3 protease-dependent bovine viral diarrhea virus

Maternal antibody blocks humoral but not T cell responses to BVDV.

Evolution of bovine viral diarrhea virus vaccines.

Development and evaluation of a replicon particle vaccine expressing the E2 glycoprotein of bovine viral diarrhea virus (BVDV) in cattle.

Pathogenesis of mucosal disease and molecular aspects of bovine virus diarrhoea virus.

Glycoprotein E2 of bovine viral diarrhea virus expressed in insect cells provides calves limited protection from systemic infection and disease.

Analysis of mRNA expression for genes associated with regulatory T lymphocytes (CD25, FoxP3, CTLA4, and IDO) after experimental infection with bovine viral diarrhea virus of low or high virulence in beef calves.

Bovine herpesvirus-1: evaluation of genetic diversity of subtypes derived from field strains of varied clinical syndromes and their relationship to vaccine strains.

Silica vesicles as nanocarriers and adjuvants for generating both antibody and T-cell mediated immune resposes to Bovine Viral Diarrhoea Virus E2 protein.

Immunogenicity of recombinant BCGs expressing predicted antigenic epitopes of bovine viral diarrhea virus E2 gene.

P304

27-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1017/S1466252315000080

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26050569

http://www.w3.org/2001/XMLSchema#string

BVDV vaccination in North America: risks versus benefits.

about

P2860

P2860

BVDV vaccination in North America: risks versus benefits.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698